Low-dose cortico steroids to treat septic shock: A critical literature review

Critical Care Nurse

Volumn 31, Issue 6, 2011, Pages 16-26

  Yarema, Tania Christine ^a,b   Yost, Spencer ^c  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UCSF's Mount Zion hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; VASOCONSTRICTOR AGENT;

ADULT; DOSE RESPONSE; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPTIC SHOCK; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SHOCK, SEPTIC; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 84860237248     PISSN: 02795442     EISSN: None     Source Type: Journal    
DOI: 10.4037/ccn2011551     Document Type: Article

References (24)

1. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet. 2005;365(9453):63-78.
2. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med. 2007;35(5):1244-1250.
3. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B; CUB-Réa Network. Current epidemiology of septic shock: the CUB-Réa Network. Am J Respir Crit Care Med. 2003;168(2):165-172.
4. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med. 2004;30(4):536-555.
5. Yadavalli GK, Salata RA. Bacteremia and sepsis syndrome. In: Andreoli T, Carpenter C, Griggs R, Lascalzo J, eds. Cecil Essentials of Medicine. 6th ed. Philadelphia, PA: WB Saunders Co; 2004:837-841.
6. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317(11):653-658.
7. Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med. 1995;23(8):1430-1439.
8. Sprung CL. Steroid therapy of septic shock. Crit Care Clin. 2009;25(4):825-834.
9. Low-dose steroid administration. Surviving Sepsis Campaign Web site. http://www.survivingsepsis.com/how_to_improve/measures_low-dose_steroid. Accessed August 27, 2011.
10. Sprung CL, Annane D, Keh D, et al; CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358(2):111-124.
11. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644-1655.
12. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32(3):858-873.
13. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008; 36(1):296-327.
14. Burry LD, Wax RS. Role of corticosteroids in septic shock. Ann Pharmacother. 2004;38: 464-472.
15. Copstead-Kirkhorn L, Banasik J. Pathophysiology. 3rd ed. St Louis, MO: Elsevier Saunders; 2005.
16. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ. 2004;329(7464): 480. doi:10.1136/bmj.38181.482222.55.
17. Annane D, Sébille V, Troché G, Raphael JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA. 2000;283(8):1038-1045.
18. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med. 1999;27(4):7237-7232.
19. Annane D, Sébille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002; 288(7):862-871.
20. Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of " low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebocontrolled, crossover study. Am J Respir Crit Care Med. 2003;167(4):5125-5120.
21. Oppert M, Schindler R, Husung C, et al. Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med. 2005;33(11):2457-2464.
22. Raurich JM, Llompart-Pou JA, Ibanez J, et al. Low-dose steroid therapy does not affect hemodynamic response in septic shock patients. J Crit Care. 2007;22(4):324-329.
23. Cuthbertson BH, Sprung CL, Annane D, et al. The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. Intensive Care Med. 2009;35(11): 1868-1876.
24. Ray DC, McKeown DW. Effect of induction agent on vasopressor and steroid use, and outcome in patients with septic shock. Critical Care. 2007;11:R56.